April 8, 2021
US-based HUYA Bioscience International has filed its cancer drug HBI-8000 (tucidinostat) for an additional indication of relapsed or refractory peripheral T-cell lymphoma (PTCL) in Japan through its local subsidiary, Japanese partner Meiji Seika Pharma said on April 7. A new...read more